Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis
Clinical Trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis
The main goal of this study is to look at the effectiveness and safety of an experimental drug called ?telitacicept? in people who have been diagnosed with generalized myasthenia gravis (gMG) and are positive for AChR antibodies or Musk antibodies.
Eligibility Criteria
- Inclusion Criteria: You are diagnosed with gMG with confirmed documentation and supported by a physical exam and confirmed positive for AChR-Antibodies or Musk-Antibodioes at screening. You have an MG-ADL total score ?6 at screening and the day 1 visit, with more than 50% of the score due to nonocular symptoms. Exclusion Criteria: You had a thymectomy within 6 months of screening or plan to have one during the study You have a history of cancer unless deemed cured by treatment with no evidence of reoccurrence for more than 5 years
RESEARCH. INNOVATION. DISCOVERY.